Lymphocyte-to-C-Reactive Protein Ratio Predicts Prognosis in Patients With Colorectal Liver Metastases Post-hepatic Resection: A Retrospective Study.


Journal

Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988

Informations de publication

Date de publication:
Oct 2022
Historique:
received: 16 07 2022
revised: 10 08 2022
accepted: 22 08 2022
entrez: 3 10 2022
pubmed: 4 10 2022
medline: 6 10 2022
Statut: ppublish

Résumé

Preoperative systemic inflammation has been reported to predict survival in patients with various cancer types. In patients with colorectal liver metastasis (CRLM), the prognosis is poor despite therapeutic advances in the field. Here, we aimed to evaluate the prognostic role of the lymphocyte-to-C-reactive protein (CRP) ratio (LCR) in patients with CRLM after hepatic resection. This retrospective study included 104 patients who underwent hepatic resection for CRLM between October 2010 and 2021 at the National Hospital Organization Fukuyama Medical Center, Hiroshima, Japan. The association between clinicopathological variables, including various inflammatory biomarkers [LCR, platelet-to-lymphocyte ratio (PLR), neutrophil-to-lymphocyte ratio (NLR), CRP-to-albumin ratio (CAR), and prognostic nutritional index (PNI)], and overall survival of the patients was investigated using univariate and multivariate analyses. The optimal cut-off values for each biomarker by receiver-operating characteristic analysis were as follows: LCR: 12,720; PLR: 150; NLR: 4; CAR: 0.023; and PNI: 44.8. The 1-, 3-, and 5-year overall survival rates were 97.0%, 71.3%, and 56.8%, respectively. On univariate analysis, LCR<12, 720, PLR<0.14, body mass index <24 kg/m LCR may be an independent prognostic predictor in patients after hepatic resection for CRLM. Therefore, the assessment of LCR as a biomarker may help in treatment planning.

Sections du résumé

BACKGROUND/AIM OBJECTIVE
Preoperative systemic inflammation has been reported to predict survival in patients with various cancer types. In patients with colorectal liver metastasis (CRLM), the prognosis is poor despite therapeutic advances in the field. Here, we aimed to evaluate the prognostic role of the lymphocyte-to-C-reactive protein (CRP) ratio (LCR) in patients with CRLM after hepatic resection.
PATIENTS AND METHODS METHODS
This retrospective study included 104 patients who underwent hepatic resection for CRLM between October 2010 and 2021 at the National Hospital Organization Fukuyama Medical Center, Hiroshima, Japan. The association between clinicopathological variables, including various inflammatory biomarkers [LCR, platelet-to-lymphocyte ratio (PLR), neutrophil-to-lymphocyte ratio (NLR), CRP-to-albumin ratio (CAR), and prognostic nutritional index (PNI)], and overall survival of the patients was investigated using univariate and multivariate analyses.
RESULTS RESULTS
The optimal cut-off values for each biomarker by receiver-operating characteristic analysis were as follows: LCR: 12,720; PLR: 150; NLR: 4; CAR: 0.023; and PNI: 44.8. The 1-, 3-, and 5-year overall survival rates were 97.0%, 71.3%, and 56.8%, respectively. On univariate analysis, LCR<12, 720, PLR<0.14, body mass index <24 kg/m
CONCLUSION CONCLUSIONS
LCR may be an independent prognostic predictor in patients after hepatic resection for CRLM. Therefore, the assessment of LCR as a biomarker may help in treatment planning.

Identifiants

pubmed: 36191973
pii: 42/10/4963
doi: 10.21873/anticanres.16003
doi:

Substances chimiques

Albumins 0
Biomarkers 0
Carbohydrates 0
C-Reactive Protein 9007-41-4

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

4963-4971

Informations de copyright

Copyright © 2022 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Auteurs

Masashi Utsumi (M)

Department of Surgery, National Hospital Organization Fukuyama Medical Center, Fukuyama, Japan masasi11232001@yahoo.co.jp.

Masaru Inagaki (M)

Department of Surgery, National Hospital Organization Fukuyama Medical Center, Fukuyama, Japan.

Koji Kitada (K)

Department of Surgery, National Hospital Organization Fukuyama Medical Center, Fukuyama, Japan.

Naoyuki Tokunaga (N)

Department of Surgery, National Hospital Organization Fukuyama Medical Center, Fukuyama, Japan.

Midori Kondo (M)

Department of Surgery, National Hospital Organization Fukuyama Medical Center, Fukuyama, Japan.

Kosuke Yunoki (K)

Department of Surgery, National Hospital Organization Fukuyama Medical Center, Fukuyama, Japan.

Yuya Sakurai (Y)

Department of Surgery, National Hospital Organization Fukuyama Medical Center, Fukuyama, Japan.

Ryosuke Hamano (R)

Department of Surgery, National Hospital Organization Fukuyama Medical Center, Fukuyama, Japan.

Hideaki Miyasou (H)

Department of Surgery, National Hospital Organization Fukuyama Medical Center, Fukuyama, Japan.

Yousuke Tsunemitsu (Y)

Department of Surgery, National Hospital Organization Fukuyama Medical Center, Fukuyama, Japan.

Shinya Otsuka (S)

Department of Surgery, National Hospital Organization Fukuyama Medical Center, Fukuyama, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH